Noida Chronicle

Neuroblastoma Overview

Neuroblastoma is a rare type of cancer that mostly affects babies and young children. It develops from specialized nerve cells (neuroblasts) left behind from a baby’s development in the womb. Neuroblastoma most commonly occurs in 1 of the adrenal glands situated above the kidneys, or in the nerve tissue that runs alongside the spinal cord in the neck, chest, tummy or pelvis. It can spread to other organs, such as the bone marrow, bone, lymph nodes, liver and skin.

“Neuroblastoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuroblastoma Market.

The Neuroblastoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Neuroblastoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Neuroblastoma treatment therapies with a considerable amount of success over the years. Neuroblastoma Key players such as – ORIC Pharmaceuticals, Inc., Aum Bio, Nano Pharmaceuticals, Athenex, Inc., Actuate Therapeutics Inc., PersonGen BioTherapeutics, KC Pharmaceuticals, Jubilant Pharmova Limited, and others, are developing therapies for the Neuroblastoma treatment 

• Neuroblastoma Emerging therapies such as – PLK4 Inhibitor Program, AUM302, BG-P-TAT, KUR-501, 9-ING-41, TAA06, DFMO (Eflornithine HCl), Iobenguane (131I), and others are expected to have a significant impact on the Neuroblastoma market in the coming years.   
• K C Pharmaceuticals initiated a trial entitled “A Phase II Preventative Trial of DFMO(Eflornithine HCl) as a Single Agent in Patients With High Risk Neuroblastoma in Remission”
• Event-free survival (EFS) and overall survival (OS) of 81 subjects with HRNB treated with standard COG induction, consolidation and immunotherapy followed by 2 years of DFMO on the NMTRC003/003b Phase II trial were compared to a historical cohort of 76 HRNB patients treated at Beat Childhood Cancer Research Consortium(BCC) hospitals who were disease-free after completion of standard upfront therapy and did not receive DFMO

Route of Administration

Neuroblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Neuroblastoma Pipeline Therapeutics Assessment

• Neuroblastoma Assessment by Product Type
• Neuroblastoma By Stage and Product Type
• Neuroblastoma Assessment by Route of Administration
• Neuroblastoma By Stage and Route of Administration
• Neuroblastoma Assessment by Molecule Type
• Neuroblastoma by Stage and Molecule Type

DelveInsight’s Neuroblastoma Report covers around 35+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Neuroblastoma Therapeutics Market include:

Key companies developing therapies for Neuroblastoma are – Clarity Pharmaceuticals Ltd, Eli Lilly and Company, Laboratorio Elea Phoenix S.A., PersonGen BioTherapeutics (Suzhou) Co., Ltd., Advanced Accelerator Applications, K C Pharmaceuticals Inc., Curis, Inc., Pfizer, Valent Technologies, LLC, UGISense AG, Y-mAbs Therapeutics, Ascentage Pharma, Kuur Therapeutics, Cell Medica, Autolus, NanoPharmaceuticals, Aptorum Group, and others.

Emerging Neuroblastoma Drugs Under Different Phases of Clinical Development Include:

• PLK4 Inhibitor Program: ORIC Pharmaceuticals, Inc.
• AUM302: Aum Bio
• BG-P-TAT: Nano Pharmaceuticals
• KUR-501: Athenex, Inc.
• 9-ING-41: Actuate Therapeutics Inc.
• TAA06: PersonGen BioTherapeutics
• DFMO (Eflornithine HCl): KC Pharmaceuticals
• Iobenguane (131I): Jubilant Pharmova Limited

Get a Free Sample PDF Report to know more about Neuroblastoma Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/neuroblastoma-pipeline-insight

Neuroblastoma Pipeline Analysis:

The Neuroblastoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Neuroblastoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuroblastoma Treatment.
• Neuroblastoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Neuroblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuroblastoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Neuroblastoma product details are provided in the report. Download the Neuroblastoma pipeline report to learn more about the emerging Neuroblastoma therapies

Neuroblastoma Pipeline Market Drivers

• Increased Incidence of Neuroblastoma worldwide
• Innovations and the new product combinations

Neuroblastoma Pipeline Market Barriers

• Lack of Awareness
• Drug-related side effects

Scope of Neuroblastoma Pipeline Drug Insight    

• Coverage: Global
• Key Neuroblastoma Companies: ORIC Pharmaceuticals, Inc., Aum Bio, Nano Pharmaceuticals, Athenex, Inc., Actuate Therapeutics Inc., PersonGen BioTherapeutics, KC Pharmaceuticals, Jubilant Pharmova Limited, and others
• Key Neuroblastoma Therapies: PLK4 Inhibitor Program, AUM302, BG-P-TAT, KUR-501, 9-ING-41, TAA06, DFMO (Eflornithine HCl), Iobenguane (131I), and others
• Neuroblastoma Therapeutic Assessment: Neuroblastoma current marketed and Neuroblastoma emerging therapies
• Neuroblastoma Market Dynamics: Neuroblastoma market drivers and Neuroblastoma market barriers 

Request for Sample PDF Report for Neuroblastoma Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Neuroblastoma drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services